Technology legitimacy and the legitimacy of technology: The case of chronic kidney disease therapies
In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed s...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Jain, Sanjay [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021transfer abstract |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: A comparison of standard hematologic testing and fibrinogen levels as predictors of mortality in severe traumatic brain injury - Peralta, Ruben ELSEVIER, 2015, JET-M, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:62 ; year:2021 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jengtecman.2021.101653 |
|---|
| Katalog-ID: |
ELV055947891 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV055947891 | ||
| 003 | DE-627 | ||
| 005 | 20230626042416.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220105s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jengtecman.2021.101653 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001608.pica |
| 035 | |a (DE-627)ELV055947891 | ||
| 035 | |a (ELSEVIER)S0923-4748(21)00042-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 540 |a 530 |q VZ |
| 084 | |a ASIEN |q DE-1a |2 fid | ||
| 084 | |a 6,25 |2 ssgn | ||
| 084 | |a 35.90 |2 bkl | ||
| 084 | |a 33.61 |2 bkl | ||
| 084 | |a 51.00 |2 bkl | ||
| 100 | 1 | |a Jain, Sanjay |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Technology legitimacy and the legitimacy of technology: The case of chronic kidney disease therapies |
| 264 | 1 | |c 2021transfer abstract | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains. | ||
| 520 | |a In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains. | ||
| 650 | 7 | |a Kidney disease |2 Elsevier | |
| 650 | 7 | |a Technology legitimacy |2 Elsevier | |
| 650 | 7 | |a Technology selection |2 Elsevier | |
| 650 | 7 | |a Historical narrative |2 Elsevier | |
| 650 | 7 | |a Legitimacy dynamics |2 Elsevier | |
| 650 | 7 | |a Medical technology |2 Elsevier | |
| 650 | 7 | |a Technology assessment |2 Elsevier | |
| 650 | 7 | |a Healthcare |2 Elsevier | |
| 650 | 7 | |a Institutional theory |2 Elsevier | |
| 700 | 1 | |a Ahlstrom, David |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Peralta, Ruben ELSEVIER |t A comparison of standard hematologic testing and fibrinogen levels as predictors of mortality in severe traumatic brain injury |d 2015 |d JET-M |g Amsterdam [u.a.] |w (DE-627)ELV013351605 |
| 773 | 1 | 8 | |g volume:62 |g year:2021 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jengtecman.2021.101653 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-ASIEN | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_40 | ||
| 936 | b | k | |a 35.90 |j Festkörperchemie |q VZ |
| 936 | b | k | |a 33.61 |j Festkörperphysik |q VZ |
| 936 | b | k | |a 51.00 |j Werkstoffkunde: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 62 |j 2021 |h 0 | ||
| author_variant |
s j sj |
|---|---|
| matchkey_str |
jainsanjayahlstromdavid:2021----:ehooyeiiaynteeiiayfehooyhcsocrn |
| hierarchy_sort_str |
2021transfer abstract |
| bklnumber |
35.90 33.61 51.00 |
| publishDate |
2021 |
| allfields |
10.1016/j.jengtecman.2021.101653 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001608.pica (DE-627)ELV055947891 (ELSEVIER)S0923-4748(21)00042-4 DE-627 ger DE-627 rakwb eng 610 VZ 540 530 VZ ASIEN DE-1a fid 6,25 ssgn 35.90 bkl 33.61 bkl 51.00 bkl Jain, Sanjay verfasserin aut Technology legitimacy and the legitimacy of technology: The case of chronic kidney disease therapies 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains. In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains. Kidney disease Elsevier Technology legitimacy Elsevier Technology selection Elsevier Historical narrative Elsevier Legitimacy dynamics Elsevier Medical technology Elsevier Technology assessment Elsevier Healthcare Elsevier Institutional theory Elsevier Ahlstrom, David oth Enthalten in Elsevier Peralta, Ruben ELSEVIER A comparison of standard hematologic testing and fibrinogen levels as predictors of mortality in severe traumatic brain injury 2015 JET-M Amsterdam [u.a.] (DE-627)ELV013351605 volume:62 year:2021 pages:0 https://doi.org/10.1016/j.jengtecman.2021.101653 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-ASIEN SSG-OLC-PHA GBV_ILN_40 35.90 Festkörperchemie VZ 33.61 Festkörperphysik VZ 51.00 Werkstoffkunde: Allgemeines VZ AR 62 2021 0 |
| spelling |
10.1016/j.jengtecman.2021.101653 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001608.pica (DE-627)ELV055947891 (ELSEVIER)S0923-4748(21)00042-4 DE-627 ger DE-627 rakwb eng 610 VZ 540 530 VZ ASIEN DE-1a fid 6,25 ssgn 35.90 bkl 33.61 bkl 51.00 bkl Jain, Sanjay verfasserin aut Technology legitimacy and the legitimacy of technology: The case of chronic kidney disease therapies 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains. In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains. Kidney disease Elsevier Technology legitimacy Elsevier Technology selection Elsevier Historical narrative Elsevier Legitimacy dynamics Elsevier Medical technology Elsevier Technology assessment Elsevier Healthcare Elsevier Institutional theory Elsevier Ahlstrom, David oth Enthalten in Elsevier Peralta, Ruben ELSEVIER A comparison of standard hematologic testing and fibrinogen levels as predictors of mortality in severe traumatic brain injury 2015 JET-M Amsterdam [u.a.] (DE-627)ELV013351605 volume:62 year:2021 pages:0 https://doi.org/10.1016/j.jengtecman.2021.101653 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-ASIEN SSG-OLC-PHA GBV_ILN_40 35.90 Festkörperchemie VZ 33.61 Festkörperphysik VZ 51.00 Werkstoffkunde: Allgemeines VZ AR 62 2021 0 |
| allfields_unstemmed |
10.1016/j.jengtecman.2021.101653 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001608.pica (DE-627)ELV055947891 (ELSEVIER)S0923-4748(21)00042-4 DE-627 ger DE-627 rakwb eng 610 VZ 540 530 VZ ASIEN DE-1a fid 6,25 ssgn 35.90 bkl 33.61 bkl 51.00 bkl Jain, Sanjay verfasserin aut Technology legitimacy and the legitimacy of technology: The case of chronic kidney disease therapies 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains. In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains. Kidney disease Elsevier Technology legitimacy Elsevier Technology selection Elsevier Historical narrative Elsevier Legitimacy dynamics Elsevier Medical technology Elsevier Technology assessment Elsevier Healthcare Elsevier Institutional theory Elsevier Ahlstrom, David oth Enthalten in Elsevier Peralta, Ruben ELSEVIER A comparison of standard hematologic testing and fibrinogen levels as predictors of mortality in severe traumatic brain injury 2015 JET-M Amsterdam [u.a.] (DE-627)ELV013351605 volume:62 year:2021 pages:0 https://doi.org/10.1016/j.jengtecman.2021.101653 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-ASIEN SSG-OLC-PHA GBV_ILN_40 35.90 Festkörperchemie VZ 33.61 Festkörperphysik VZ 51.00 Werkstoffkunde: Allgemeines VZ AR 62 2021 0 |
| allfieldsGer |
10.1016/j.jengtecman.2021.101653 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001608.pica (DE-627)ELV055947891 (ELSEVIER)S0923-4748(21)00042-4 DE-627 ger DE-627 rakwb eng 610 VZ 540 530 VZ ASIEN DE-1a fid 6,25 ssgn 35.90 bkl 33.61 bkl 51.00 bkl Jain, Sanjay verfasserin aut Technology legitimacy and the legitimacy of technology: The case of chronic kidney disease therapies 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains. In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains. Kidney disease Elsevier Technology legitimacy Elsevier Technology selection Elsevier Historical narrative Elsevier Legitimacy dynamics Elsevier Medical technology Elsevier Technology assessment Elsevier Healthcare Elsevier Institutional theory Elsevier Ahlstrom, David oth Enthalten in Elsevier Peralta, Ruben ELSEVIER A comparison of standard hematologic testing and fibrinogen levels as predictors of mortality in severe traumatic brain injury 2015 JET-M Amsterdam [u.a.] (DE-627)ELV013351605 volume:62 year:2021 pages:0 https://doi.org/10.1016/j.jengtecman.2021.101653 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-ASIEN SSG-OLC-PHA GBV_ILN_40 35.90 Festkörperchemie VZ 33.61 Festkörperphysik VZ 51.00 Werkstoffkunde: Allgemeines VZ AR 62 2021 0 |
| allfieldsSound |
10.1016/j.jengtecman.2021.101653 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001608.pica (DE-627)ELV055947891 (ELSEVIER)S0923-4748(21)00042-4 DE-627 ger DE-627 rakwb eng 610 VZ 540 530 VZ ASIEN DE-1a fid 6,25 ssgn 35.90 bkl 33.61 bkl 51.00 bkl Jain, Sanjay verfasserin aut Technology legitimacy and the legitimacy of technology: The case of chronic kidney disease therapies 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains. In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains. Kidney disease Elsevier Technology legitimacy Elsevier Technology selection Elsevier Historical narrative Elsevier Legitimacy dynamics Elsevier Medical technology Elsevier Technology assessment Elsevier Healthcare Elsevier Institutional theory Elsevier Ahlstrom, David oth Enthalten in Elsevier Peralta, Ruben ELSEVIER A comparison of standard hematologic testing and fibrinogen levels as predictors of mortality in severe traumatic brain injury 2015 JET-M Amsterdam [u.a.] (DE-627)ELV013351605 volume:62 year:2021 pages:0 https://doi.org/10.1016/j.jengtecman.2021.101653 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-ASIEN SSG-OLC-PHA GBV_ILN_40 35.90 Festkörperchemie VZ 33.61 Festkörperphysik VZ 51.00 Werkstoffkunde: Allgemeines VZ AR 62 2021 0 |
| language |
English |
| source |
Enthalten in A comparison of standard hematologic testing and fibrinogen levels as predictors of mortality in severe traumatic brain injury Amsterdam [u.a.] volume:62 year:2021 pages:0 |
| sourceStr |
Enthalten in A comparison of standard hematologic testing and fibrinogen levels as predictors of mortality in severe traumatic brain injury Amsterdam [u.a.] volume:62 year:2021 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Festkörperchemie Festkörperphysik Werkstoffkunde: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Kidney disease Technology legitimacy Technology selection Historical narrative Legitimacy dynamics Medical technology Technology assessment Healthcare Institutional theory |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
A comparison of standard hematologic testing and fibrinogen levels as predictors of mortality in severe traumatic brain injury |
| authorswithroles_txt_mv |
Jain, Sanjay @@aut@@ Ahlstrom, David @@oth@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
ELV013351605 |
| dewey-sort |
3610 |
| id |
ELV055947891 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV055947891</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626042416.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jengtecman.2021.101653</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001608.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV055947891</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0923-4748(21)00042-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="a">530</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">ASIEN</subfield><subfield code="q">DE-1a</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">6,25</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.90</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">33.61</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Jain, Sanjay</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Technology legitimacy and the legitimacy of technology: The case of chronic kidney disease therapies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Kidney disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Technology legitimacy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Technology selection</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Historical narrative</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Legitimacy dynamics</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medical technology</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Technology assessment</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Healthcare</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Institutional theory</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ahlstrom, David</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Peralta, Ruben ELSEVIER</subfield><subfield code="t">A comparison of standard hematologic testing and fibrinogen levels as predictors of mortality in severe traumatic brain injury</subfield><subfield code="d">2015</subfield><subfield code="d">JET-M</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV013351605</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:62</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jengtecman.2021.101653</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-ASIEN</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.90</subfield><subfield code="j">Festkörperchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">33.61</subfield><subfield code="j">Festkörperphysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">62</subfield><subfield code="j">2021</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Jain, Sanjay |
| spellingShingle |
Jain, Sanjay ddc 610 ddc 540 fid ASIEN ssgn 6,25 bkl 35.90 bkl 33.61 bkl 51.00 Elsevier Kidney disease Elsevier Technology legitimacy Elsevier Technology selection Elsevier Historical narrative Elsevier Legitimacy dynamics Elsevier Medical technology Elsevier Technology assessment Elsevier Healthcare Elsevier Institutional theory Technology legitimacy and the legitimacy of technology: The case of chronic kidney disease therapies |
| authorStr |
Jain, Sanjay |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV013351605 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 540 - Chemistry & allied sciences 530 - Physics |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 540 530 VZ ASIEN DE-1a fid 6,25 ssgn 35.90 bkl 33.61 bkl 51.00 bkl Technology legitimacy and the legitimacy of technology: The case of chronic kidney disease therapies Kidney disease Elsevier Technology legitimacy Elsevier Technology selection Elsevier Historical narrative Elsevier Legitimacy dynamics Elsevier Medical technology Elsevier Technology assessment Elsevier Healthcare Elsevier Institutional theory Elsevier |
| topic |
ddc 610 ddc 540 fid ASIEN ssgn 6,25 bkl 35.90 bkl 33.61 bkl 51.00 Elsevier Kidney disease Elsevier Technology legitimacy Elsevier Technology selection Elsevier Historical narrative Elsevier Legitimacy dynamics Elsevier Medical technology Elsevier Technology assessment Elsevier Healthcare Elsevier Institutional theory |
| topic_unstemmed |
ddc 610 ddc 540 fid ASIEN ssgn 6,25 bkl 35.90 bkl 33.61 bkl 51.00 Elsevier Kidney disease Elsevier Technology legitimacy Elsevier Technology selection Elsevier Historical narrative Elsevier Legitimacy dynamics Elsevier Medical technology Elsevier Technology assessment Elsevier Healthcare Elsevier Institutional theory |
| topic_browse |
ddc 610 ddc 540 fid ASIEN ssgn 6,25 bkl 35.90 bkl 33.61 bkl 51.00 Elsevier Kidney disease Elsevier Technology legitimacy Elsevier Technology selection Elsevier Historical narrative Elsevier Legitimacy dynamics Elsevier Medical technology Elsevier Technology assessment Elsevier Healthcare Elsevier Institutional theory |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
d a da |
| hierarchy_parent_title |
A comparison of standard hematologic testing and fibrinogen levels as predictors of mortality in severe traumatic brain injury |
| hierarchy_parent_id |
ELV013351605 |
| dewey-tens |
610 - Medicine & health 540 - Chemistry 530 - Physics |
| hierarchy_top_title |
A comparison of standard hematologic testing and fibrinogen levels as predictors of mortality in severe traumatic brain injury |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV013351605 |
| title |
Technology legitimacy and the legitimacy of technology: The case of chronic kidney disease therapies |
| ctrlnum |
(DE-627)ELV055947891 (ELSEVIER)S0923-4748(21)00042-4 |
| title_full |
Technology legitimacy and the legitimacy of technology: The case of chronic kidney disease therapies |
| author_sort |
Jain, Sanjay |
| journal |
A comparison of standard hematologic testing and fibrinogen levels as predictors of mortality in severe traumatic brain injury |
| journalStr |
A comparison of standard hematologic testing and fibrinogen levels as predictors of mortality in severe traumatic brain injury |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Jain, Sanjay |
| container_volume |
62 |
| class |
610 VZ 540 530 VZ ASIEN DE-1a fid 6,25 ssgn 35.90 bkl 33.61 bkl 51.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Jain, Sanjay |
| doi_str_mv |
10.1016/j.jengtecman.2021.101653 |
| dewey-full |
610 540 530 |
| title_sort |
technology legitimacy and the legitimacy of technology: the case of chronic kidney disease therapies |
| title_auth |
Technology legitimacy and the legitimacy of technology: The case of chronic kidney disease therapies |
| abstract |
In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains. |
| abstractGer |
In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains. |
| abstract_unstemmed |
In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-ASIEN SSG-OLC-PHA GBV_ILN_40 |
| title_short |
Technology legitimacy and the legitimacy of technology: The case of chronic kidney disease therapies |
| url |
https://doi.org/10.1016/j.jengtecman.2021.101653 |
| remote_bool |
true |
| author2 |
Ahlstrom, David |
| author2Str |
Ahlstrom, David |
| ppnlink |
ELV013351605 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1016/j.jengtecman.2021.101653 |
| up_date |
2024-07-06T18:59:07.685Z |
| _version_ |
1803857268766146560 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV055947891</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626042416.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jengtecman.2021.101653</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001608.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV055947891</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0923-4748(21)00042-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="a">530</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">ASIEN</subfield><subfield code="q">DE-1a</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">6,25</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.90</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">33.61</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Jain, Sanjay</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Technology legitimacy and the legitimacy of technology: The case of chronic kidney disease therapies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In this paper we explore how the institutional environment in which technologies are embedded serves to select certain technological options while marginalizing others. To do this, we trace the activities occurring among and between sponsors and the legitimacy assemblage – that is, the distributed set of actors, materials and methodologies that collectively confer legitimacy to a technology. Specifically, we employ an analytic narrative of the evolution of chronic kidney disease (CKD) treatment modalities to demonstrate how dialysis has become an accepted form of treatment while an effective preventative and complementary treatment, dietary protein restriction (DPR), has been marginalized. Our account highlights the emergence of a legitimacy assemblage that establishes the boundaries of what constitutes an appropriate technology, the bandwagon process by which technologies accrue legitimacy, and how actors subsequently engage in legitimacy capture that can contribute to technology stagnation in a domain. In highlighting these legitimacy dynamics, we provide new insights to the literature on technology selection, develop an expanded elaboration of technology legitimacy, and also offer insights for the medical and healthcare policy domains.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Kidney disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Technology legitimacy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Technology selection</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Historical narrative</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Legitimacy dynamics</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medical technology</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Technology assessment</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Healthcare</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Institutional theory</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ahlstrom, David</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Peralta, Ruben ELSEVIER</subfield><subfield code="t">A comparison of standard hematologic testing and fibrinogen levels as predictors of mortality in severe traumatic brain injury</subfield><subfield code="d">2015</subfield><subfield code="d">JET-M</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV013351605</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:62</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jengtecman.2021.101653</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-ASIEN</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.90</subfield><subfield code="j">Festkörperchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">33.61</subfield><subfield code="j">Festkörperphysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">62</subfield><subfield code="j">2021</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.4019423 |